Journal of Oncology Pharmacy Practice最新文献

{"title":"A prospective analysis of efficacy of dexamethasone-sparing antiemetic regimens in high and moderate emetogenic chemotherapy.","authors":"Naveenraj Viswanathan, Harish Kamaraj, Ardhra Jiju, R V Viknesh, Ram Abhinav Kannan, Velusamy Premsundari","doi":"10.1177/10781552251330811","DOIUrl":"10.1177/10781552251330811","url":null,"abstract":"<p><p>ObjectivesMultiple moderate-to-severe side effects associated with dexamethasone (DEX) were observed by patients undergoing a multi-day DEX regimen for delayed chemotherapy-induced nausea and vomiting (CINV). Therefore, there is increasing demand in clinical practice to lower DEX doses in subsequent emetogenic treatment cycles. This study aimed to evaluate the efficacy of the DEX-sparing antiemetic regimens in high- and moderate- emetogenic chemotherapy (HEC, MEC respectively) and to explore its functional impact on health-related Quality of Life (QoL).Materials and methodsThis is a prospective, observational study that includes 91 patients who received HEC and MEC with DEX. We evaluated the percentage of complete response and complete control of CINV in acute phases (<24 h) and delayed phases (25-120 h). The Functional Living Index-Emesis (FLIE), a 5-day recall tool, was used to evaluate the functional impact of DEX-sparing regimens on health-related QoL. Nausea and vomiting were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.Statistical analysisThe SPSS version 20.0 was used for the statistical analysis. In the descriptive analysis, the study's parameters were analyzed and their mean (±SD), percentage, and frequency were determined.ResultsIn terms of overall efficacy, the DEX sparing was 86.36% in complete control and 90.91% in complete response. In the CTCAE version 5.0 analyses, only 1.1% of cases were reported with a Grade 3, and none with a Grade 4 or Grade 5. The FLIE score was above 54 in each domain, indicating no impact of CINV on daily life.ConclusionThe use of DEX-sparing antiemetic regimens in clinical settings, which can be better tolerated by patients, is made clear by this study. Consequently, our findings guide clinicians to optimize the use of DEX to preserve anti-emetic efficacy throughout the scheduled cycles of emetogenic chemotherapy.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"986-992"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143743151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing antineoplastic drug contamination in South African oncology pharmacies: Workplace and biological monitoring.","authors":"Ruan Botha, Gill Nelson, Paul Sessink, Derk Brouwer","doi":"10.1177/10781552251321150","DOIUrl":"10.1177/10781552251321150","url":null,"abstract":"<p><p>IntroductionAntineoplastic drugs (ADs) are hazardous substances commonly used in medical oncology, posing health risks to pharmacy personnel through occupational exposure. Despite safety guidelines, contamination of surfaces in oncology pharmacies remains prevalent. In this study, we assessed surface contamination and biological uptake of ADs in selected South African oncology pharmacies.MethodsSix pharmacies (three from each of two medical oncology service providers, SP1 and SP2) participated. Surface wipe samples were collected from three areas in each pharmacy (containment-primary engineering control (C-PEC), floor, adjacent surface) before and after decontamination procedures. Nine ADs were quantified, using high-pressure liquid chromatography tandem mass spectrometry (HPLC-MS/MS). 24-h urine samples were collected from six pharmacy personnel. The DeRmal Exposure Assessment Method (DREAM) was used to estimate exposure risks. The results were compared with those from an observational study that assessed compliance with safety protocols in the same six pharmacies.ResultsSurface contamination was higher in SP1 than in SP2 pharmacies, with 5-fluorouracil (5-FU) being the most frequently detected AD. Post-decontamination samples showed a 17.4% reduction in 5-FU contamination, although SP1 pharmacies still had higher post-decontamination concentrations than SP2 pharmacies, especially on floors. Cyclophosphamide and ifosphamide were detected in the urine of two participants from SP1.ConclusionWe demonstrated higher contamination and occupational exposure risks in SP1 than in SP2 pharmacies, indicating a need for strict decontamination protocols and better use of personal protective equipment in the SP1 pharmacies. The SP2 pharmacies may serve as a model for oncology pharmacy safety in South Africa.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1066-1075"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13490688/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143483472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antiandrogen therapies: Management of drug interactions with anticoagulation.","authors":"Arianne Duong, Hanh Bui, Dane Fritzsche, Andrew Ruplin","doi":"10.1177/10781552251406879","DOIUrl":"10.1177/10781552251406879","url":null,"abstract":"<p><p>BackgroundSecond-generation antiandrogens have significantly improved outcomes in patients with prostate cancer; however, their complex pharmacokinetic profiles can result in significant drug-drug interactions (DDIs) in patients with comorbid conditions which require chronic anticoagulation.ObjectiveThis review aims to describe the DDIs between antiandrogens and commonly used anticoagulants, with a focus on understanding the clinical implications of pharmacokinetics and drug metabolism.MethodsA comprehensive literature review of pharmacokinetic data, clinical trials, and prescribing information was performed. Drug metabolism of antiandrogens and anticoagulants was examined, including the effects of CYP450 enzyme and/or P-glycoprotein (P-gp) inhibition and induction on anticoagulant efficacy and safety.ResultsEnzalutamide and apalutamide are strong inducers of CYP3A4, which may reduce exposure to warfarin, apixaban, and rivaroxaban. Apalutamide induces P-gp, and therefore has DDIs with all direct oral anticoagulants (DOACs). Darolutamide and abiraterone exhibit minimal CYP450 induction and inhibition, and do not interact with warfarin or DOACs.ConclusionDrug-drug interactions between antiandrogens and anticoagulants are common and can affect therapeutic efficacy and safety. Clinical decision-making surrounding drug selection requires an interprofessional approach grounded in pharmacokinetic knowledge to ensure safe and effective care in patients with prostate cancer.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1126-1131"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145810490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pembrolizumab-associated exacerbation of lichen planopilaris in a patient with metastatic melanoma.","authors":"Hudson Dutra Rezende, Thiago Bianco Leal, Maria Fernanda Reis Gavazzoni Dias, Gabriela Sartori Fiorese","doi":"10.1177/10781552261416060","DOIUrl":"10.1177/10781552261416060","url":null,"abstract":"<p><strong>Introduction: </strong>Immune checkpoint inhibitors (ICIs) can trigger cutaneous immune-related adverse events (irAEs), including rare follicular eruptions such as lichen planopilaris (LPP).</p><p><strong>Case report: </strong>We report a 75-year-old woman with stable, biopsy-proven LPP who developed disease reactivation after ten cycles of pembrolizumab for stage IIC melanoma.</p><p><strong>Management & outcome: </strong>Despite ongoing treatment with hydroxychloroquine and topical clobetasol, disease activity progressed. Oral doxycycline was added. After ten months of adjunctive therapy and completion of pembrolizumab, the disease stabilized, though areas of scarring alopecia persisted. The patient remains under multidisciplinary follow-up.</p><p><strong>Discussion: </strong>LPP is an underrecognized follicular irAE. The timing, clinical course, and histopathologic findings suggest pembrolizumab-induced exacerbation. Causality was assessed using the Naranjo Algorithm, with a score of 6, indicating a probable adverse drug reaction. This case reinforces the importance of early recognition and tailored dermatologic care in patients receiving ICI therapy.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1174-1176"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146105840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The French Society for Pharmacy Oncology's commentary on the article by Iannopollo M., published in April 2026 and titled \"Rethinking centralised oncology pharmacy practice in the era of flat-dose immunotherapy, subcutaneous formulations and visit-administration day separation: A conceptual analysis and reform proposal\".","authors":"Florence Ranchon, Nicolas Cormier, Jean-Louis Cazin, Bertrand Pourroy","doi":"10.1177/10781552261451489","DOIUrl":"10.1177/10781552261451489","url":null,"abstract":"","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1182-1185"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147973287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and implementation of a pharmacy introductory cancer care program: Impacts on employee knowledge, engagement and retention.","authors":"Liam King, Anastasia Peripetsakis, Alborz Soroush, Ella Raguz","doi":"10.1177/10781552251330158","DOIUrl":"10.1177/10781552251330158","url":null,"abstract":"<p><p>IntroductionProvision of education and training is essential when transitioning staff into specialist practice areas within pharmacy. While many professional organisations provide high-quality cancer/oncology education programs, they are non-specific to the policies, workflows, and resources of service providers. Furthermore, effective training and education programs can be a tool to increase staff engagement and retention. Our organisation developed a pharmacy Introduction to Cancer Care (ICC) program to address these needs.MethodThe ICC program utilised online learning modules and a two-day face-to-face workshop. The program targeted pharmacists, intern pharmacists and pharmacy technicians new to cancer care and was facilitated by experienced pharmacists. Two evaluations were provided to participants, the first immediately post-program completion and the second, one-month post-program completion. The evaluations contained questions answered on a Likert Scale. Finally, staff retention rates were calculated at 6 months post-program.ResultsFour sessions of the program were conducted between April 2023 and April 2024, with 24 pharmacists, six intern pharmacists and five technicians completing the program. Of the participants 89% (n = 31) provided responses to the evaluation on program completion and 31% (n = 9) to the evaluation at one-month post-program completion. Retention rates at six months post-program were found to be 100% for pharmacists (n = 24), intern pharmacists (n = 6) and technicians (n = 5).ConclusionEvaluation responses were overwhelmingly positive, with all participants finding the program beneficial, increasing their interest in cancer care. Finally, all participants were still employed at the organisation six months post-program completion. Our program demonstrates ability of effective training and education programs to enhance staff learning and have positive impacts on engagement.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1024-1031"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative incidence of peripheral neuropathy associated with taxane chemotherapy in patients with breast cancer: A network meta-analysis.","authors":"Samineh Beheshtirouy, Zeinab Nikniaz, Saba Ghaffary, Raha Jaberi, Elnaz Shaseb","doi":"10.1177/10781552251405216","DOIUrl":"10.1177/10781552251405216","url":null,"abstract":"<p><p>IntroductionTaxane-induced peripheral neuropathy (TIPN) is a common toxicity among patients with breast cancer (BC). Numerous pairwise comparisons have been performed to evaluate neuropathy associated with different taxane agents (docetaxel, paclitaxel, cabazitaxel, nab-paclitaxel, liposomal paclitaxel, and paclitaxel injection concentrate for nanodispersion [PICN]). This network meta-analysis aimed to study the comparative incidence of TIPN associated with taxane agents in females with BC.MethodsA comprehensive data search was performed in PubMed, Web of Science, and Scopus up to August 2024. The studies that compare neuropathy in taxane agents were systematically reviewed. A network meta-analysis was carried out based on a Bayesian framework to evaluate the incidence of peripheral neuropathy in taxanes compared to paclitaxel, as reference comparator. The Surface Under the Cumulative Ranking Curve (SUCRA) was used to rank taxanes based on their neuropathy.ResultsA total of 27 studies with 12101 patients were included. When compared with paclitaxel, nab-paclitaxel was associated with a significantly higher incidence of peripheral neuropathy (OR: 1.74, CrI: 1.22-2.48). Docetaxel (OR: 0.626, CrI: 0.441-0.881) and cabazitaxel (OR: 0.158, CrI: 0.0664-0.375) demonstrated a significantly lower incidence of peripheral neuropathy compared to paclitaxel. Liposomal paclitaxel and PICN lack significant difference compared to paclitaxel. Our analysis provided the order for peripheral neuropathy (from lowest to highest) as follows: cabazitaxel, docetaxel, liposomal paclitaxel, paclitaxel, PICN, nab-paclitaxel.ConclusionsNab-paclitaxel is associated with a significantly higher incidence of peripheral neuropathy compared to paclitaxel in females with BC. Docetaxel and cabazitaxel are linked with less peripheral neuropathy compared with paclitaxel in this population. No significant differences were observed in liposomal paclitaxel and PICN compared to paclitaxel.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1153-1167"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145756882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishing comprehensive oncology-haematology pharmacy care for paediatric bone marrow transplantation in sickle cell disease: Procedural insights from a Delphi study conducted in Tanzania.","authors":"Kauke Bakari Zimbwe, David Simon Shau, Yusto Julius Yona, Ibrahim Philemon Bura, Mkapa Faustine Madebele","doi":"10.1177/10781552261481538","DOIUrl":"https://doi.org/10.1177/10781552261481538","url":null,"abstract":"<p><p>BackgroundHematopoietic stem cell transplantation (HSCT) is vital for treating blood disorders, yet Low- and Middle-Income Countries (LMICs) often lack adequate Bone Marrow Transplant (BMT) pharmacy services. This study aims to reach consensus among oncology pharmacy experts on the essential staff, infrastructure, supplies, and safety/control measures required to establish BMT pharmacy services in LMICs.MethodologyThe Delphi method was employed to evaluate and achieve consensus on BMT pharmacy services at Benjamin Mkapa Hospital in Tanzania, involving 11 oncology pharmacy personnel.ResultsIn the initial round, participants responded to 10 open-ended questions concerning staffing, infrastructure, supplies, medicines, safety, and quality assurance. The second round focused on achieving consensus, breaking down the domains into 14 specific points. Consensus scores varied from 64% (neutral) for safety and quality assurance to 96% for staffing levels, with consensus reached at 66.7%. The third round concentrated on prioritization, identifying staffing and infrastructure as high priorities, which received a score of 46%. Safety and quality assurance garnered the lowest score at 9%. Participants proposed two guidelines, three protocols, and 21 standard operating procedures (SOPs). Additionally, they suggested 14 essential medicines, 56 adjunctive medicines, 22 medical devices, and at least two Class III biosafety cabinets, which are crucial for establishing BMT pharmacy units and HSCT services in resource-limited settings. These resources were categorized into those already established at BMH and those that emerged from participant consensus.ConclusionsThe Delphi findings highlight staffing and infrastructure as top priorities for establishing BMT and HSCT services in resource-limited settings. Addressing safety and quality assurance is also crucial. The recommended guidelines and protocols can enhance service delivery and improve patient outcomes.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261481538"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148874450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From supportive galenic compounding to advanced clinical pharmacy: A decade of excellence and safety in the Antiblastic Drugs Unit in Southern Italy (2014-2025).","authors":"Filomena D'Amico, Rosa Moscogiuri, Loredana Brandi, Francesco Colasuonno, Mariangela Calcagno, Alessandro Maggi, Claudia Ingrosso, Tiziana Guarino, Antonio Ungaro, Vito Gregorio Colacicco, Salvatore Pisconti","doi":"10.1177/10781552261481419","DOIUrl":"https://doi.org/10.1177/10781552261481419","url":null,"abstract":"<p><p>ObjectivesAntiblastic Drugs Units (ADUs) ensure safety, appropriateness and sustainability of oncology treatments. Over the last decade, hospital pharmacists have expanded their role from aseptic compounding to advanced clinical pharmacy. This study describes the ten-year evolution of the ADU of ASL Taranto in Southern Italy, focusing on clinical, organisational and strategic value generated from 2014 to 2025.MethodsA retrospective descriptive analysis of activity data, organisational changes and clinical pharmacy services was conducted. Key indicators include compounded preparations, quality systems, technological innovations, service centralisation, CAR-T therapy management, clinical trials, compassionate use programmes and COVID-19 emergency response.ResultsBetween March and December 2014, 17,508 antiblastic preparations were compounded (daily average: 83). Activity increased to 53,300 in 2025 (daily average: 212), representing a 204% increase. The ADU achieved and maintained ISO 9001:2015 certification since 2017. Since 2022, 49 CAR-T therapies were managed, including quality assurance and AIFA registry monitoring. The ADU evolved into a Clinical Trial Centre, supporting six phase II-III trials in 2025, and enabled access to innovative medicines through compassionate use programmes (62 patients in 2025). During COVID-19, the unit served as central hub for vaccine and remdesivir management. Despite a 1194% increase in pharmaceutical expenditure (€2.54 M to €32.87 M), systematic reimbursement management generated €8.92 M in recoveries and savings in 2025 (27.1% of expenditure).ConclusionsThe experience of this ADU illustrates how a structured, quality-driven approach can support the transformation of aseptic compounding into advanced clinical pharmacy. The integration of pharmacists into multidisciplinary oncology teams was associated with strengthened medication safety processes, expanded access to innovation and improved economic sustainability, suggesting a potential reference model for comparable settings.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261481419"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148874496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing intermittent dosing of oral small molecule inhibitors.","authors":"Jina Yun, Amy Ly Indorf","doi":"10.1177/10781552251327598","DOIUrl":"10.1177/10781552251327598","url":null,"abstract":"<p><p>IntroductionWith recent expansion of oral small molecule inhibitors, the drug development studies need to provide insight into optimal dose selection for these agents with vastly different mechanism and pharmacokinetic considerations compared to our traditional chemotherapy agents. Currently there is one published meta-analysis that examines intermittent and alternative dosing of oral small molecule inhibitors and it is unclear what guidance is available for treatment personalization beyond package insert labeling for patients undergoing toxicities from treatment.MethodsA systematic review of oral small molecule inhibitors with intermittent dosing was conducted in the National Library of Medicine PubMed database. Studies were selected based on predefined inclusion/exclusion criteria. Data was extracted to summarize findings on available guidance for intermittent or alternative dosing of oral small molecule inhibitors. Studies were categorized based on food and drug administration (FDA) approved or non-FDA approved agents, and further characterized by comparison of different dosing schemas.ResultsFifty-five trials were included in the final review and data analysis. Thirty-three trials were phase 1 trials, 26 trials for FDA approved agents and 29 non-FDA approved agents. Most trials reported on agents used in solid tumors, particularly renal cell carcinoma, with most trials examining sunitinib. Of the 55 trials, 28 compared different dosing strategies with 26 of the 28 trials examining efficacy outcomes with 27 of the 28 trials examining safety outcomes.ConclusionsThis systematic review found limited guidance for clinicians in optimizing dosing for intermittently dosed oral small molecule inhibitors.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1107-1125"},"PeriodicalIF":1.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}